MARKET

VCNX

VCNX

Vaccinex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.960
-0.400
-11.90%
After Hours: 2.950 -0.01 -0.34% 19:53 03/04 EST
OPEN
3.340
PREV CLOSE
3.360
HIGH
3.430
LOW
2.860
VOLUME
1.47M
TURNOVER
--
52 WEEK HIGH
9.56
52 WEEK LOW
1.630
MARKET CAP
66.26M
P/E (TTM)
-1.7409
1D
5D
1M
3M
1Y
5Y
TDOC, EDIT among premarket gainers
IT Tech Packaging (ITP) -23% on stock offering.Ping Identity Holding (PING) -14% on Q4 results.ReTo Eco-Solutions (RETO) -10%.United States Antimony (UAMY) -9%.BioCryst Pharmaceuticals (BCRX) -9% on Q4 earnings.Best Buy (BBY) -7% on Q4 results.Chimerix
Seekingalpha · 02/25 13:13
Vascular Biogenics, Sunesis Pharmaceuticals leads healthcare gainers; Isoray, Vaccine among major losers
Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed PAVM -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics ONTX -15%, electroCore (ECOR) -14%.
Seekingalpha · 02/23 16:03
Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Cancer
PALM BEACH,  Fla., /PRNewswire/ -- In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to come. T-cell therap...
PR Newswire - PRF · 02/23 13:30
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 02/23 12:25
Vaccinex announces licensing deal with Surface Oncology
Vaccinex (VCNX) rose ~4.5% today after announcing a licensing agreement with Surface Oncology for anti-CCR8 antibody discovered via Vaccinex’s ActivMAb antibody discovery and viral display platform.Per the terms of the agreement, Surface Oncology will
Seekingalpha · 02/22 21:14
Making Up Lost Ground Through Smaller Size And Fewer Drawdowns
Last week was another intense one in the stock market. Though, despite the continued volatility, I have managed to get my P/L ratio back into line by capitalizing on the opportunities in front of me and knowing when to walk away.
Benzinga · 02/22 19:06
BRIEF-Vaccinex Announces Licensing Of Anti-Ccr8 Antibody To Surface Oncology
reuters.com · 02/22 13:59
Vaccinex Reports Surface Oncology Will Be Exercising Its Option To License Anti-CCR8 Antibody Discovered By Vaccinex's ActivMAb Platform, No Terms Disclosed
Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Surface
Benzinga · 02/22 13:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VCNX. Analyze the recent business situations of Vaccinex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VCNX stock price target is 13.50 with a high estimate of 20.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 34
Institutional Holdings: 510.75K
% Owned: 2.28%
Shares Outstanding: 22.39M
TypeInstitutionsShares
Increased
6
97.53K
New
13
-23.63K
Decreased
4
32.15K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About VCNX
Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.

Webull offers kinds of Vaccinex Inc stock information, including NASDAQ:VCNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCNX stock methods without spending real money on the virtual paper trading platform.